Scandinavian ChemoTech has passed the final revision of IQwave and increases its chances of CE marking before the deadline

ChemoTech can now sum up great progress after completing the three-day long and intensive revision of the Company's quality system and review of its critical processes required for CE marking of medical devices in the EU.

After a comprehensive revision (on-site - via video) of the Company's quality system and all processes prior to the CE marking, which was carried out last week, only a final review of a few documents submitted on 12 May now remains.

“Even though we have not secured our CE marking yet, we are proud to have passed the physical revision, which is the most critical part of the process. This definitely strengthens the Company's chances of fully securing the CE marking under the current regulations.” - says Mohan Frick, CEO of Scandinavian ChemoTech

For further information please contact: Mohan Frick, CEO

+46 (0)10-218 93 00

Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00E-mail:

Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: